These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23906044)

  • 1. N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
    Brossard D; Zhang Y; Haider SM; Sgobba M; Khalid M; Legay R; Duterque-Coquillaud M; Galera P; Rault S; Dallemagne P; Moslemi S; El Kihel L
    Chem Biol Drug Des; 2013 Nov; 82(5):620-9. PubMed ID: 23906044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
    DeVore NM; Scott EE
    Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
    Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
    J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of new steroidal pyridines as potential anti-prostate cancer agents.
    Shi YK; Wang B; Shi XL; Zhao YD; Yu B; Liu HM
    Eur J Med Chem; 2018 Feb; 145():11-22. PubMed ID: 29310026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
    Nikolić AR; Petri ET; Klisurić OR; Ćelić AS; Jakimov DS; Djurendić EA; Penov Gaši KM; Sakač MN
    Bioorg Med Chem; 2015 Feb; 23(4):703-11. PubMed ID: 25619894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone.
    Garrido M; Peng HM; Yoshimoto FK; Upadhyay SK; Bratoeff E; Auchus RJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():1-10. PubMed ID: 24508512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and antiproliferative activity evaluation of steroidal imidazo[1,2-a]pyridines.
    Rassokhina IV; Volkova YA; Kozlov AS; Scherbakov AM; Andreeva OE; Shirinian VZ; Zavarzin IV
    Steroids; 2016 Sep; 113():29-37. PubMed ID: 27263438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, 17α-hydroxylase-C
    Banday AH; Shameem SA; Banday JA; Ganaie BA
    Anticancer Agents Med Chem; 2018; 18(13):1919-1926. PubMed ID: 29697032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors.
    Jarman M; Barrie SE; Llera JM
    J Med Chem; 1998 Dec; 41(27):5375-81. PubMed ID: 9876107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of new steroidal imidazo [1,2-a] pyridines: DNA binding studies, cleavage activity and in vitro cytotoxicity.
    Dar AM; Shamsuzzaman ; Gatoo MA
    Steroids; 2015 Dec; 104():163-75. PubMed ID: 26433147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity.
    Sucman NS; Ya Bilan D; Cojocari SV; Pogrebnoi VS; Stîngaci EP; Khripach VA; Zhabinskii VN; Tsybruk TV; Grabovec IP; Panibrat OV; Persoons L; Schols D; Froeyen M; Shova S; De Jonghe S; Macaev FZ
    Steroids; 2024 Oct; 210():109475. PubMed ID: 39067611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
    Attard G; Reid AH; Auchus RJ; Hughes BA; Cassidy AM; Thompson E; Oommen NB; Folkerd E; Dowsett M; Arlt W; de Bono JS
    J Clin Endocrinol Metab; 2012 Feb; 97(2):507-16. PubMed ID: 22170708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the study of steroidal inhibitors of cytochrome P45017alpha].
    Du JJ; Chen HL; Li YC
    Yao Xue Xue Bao; 2013 Jan; 48(1):25-31. PubMed ID: 23600137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid-nucleosides analogues.
    Huang LH; Xu HD; Yang ZY; Zheng YF; Liu HM
    Steroids; 2014 Apr; 82():1-6. PubMed ID: 24378780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of [17(20)E]-21-Norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth.
    Zolottsev VA; Tkachev YV; Latysheva AS; Kostin VA; Novikov RA; Timofeev VP; Morozevich GE; Kuzikov AV; Shumyantseva VV; Misharin AY
    Steroids; 2018 Jan; 129():24-34. PubMed ID: 29183745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents.
    Eilon GF; Gu J; Slater LM; Hara K; Jacobs JW
    Cancer Chemother Pharmacol; 2000; 45(3):183-91. PubMed ID: 10663635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
    Bordeau BM; Ciulla DA; Callahan BP
    ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways.
    Grossebrummel H; Peter T; Mandelkow R; Weiss M; Muzzio D; Zimmermann U; Walther R; Jensen F; Knabbe C; Zygmunt M; Burchardt M; Stope MB
    Int J Oncol; 2016 Feb; 48(2):793-800. PubMed ID: 26648519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
    Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
    Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.